# Dragoş Vinereanu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dragos-vinereanu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 54,507 |
| Field | Cardiovascular Function and Risk Factors |
| h-index | 83 |
| i10-index | 198 |
| Last Known Institution | Carol Davila University of Medicine and Pharmacy |
| OpenAlex ID | https://openalex.org/A5011747612 |
| ORCID iD | https://orcid.org/0000-0002-9054-8779 |
| Works | 593 |

## Researcher papers

- [Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://scholariq.org/papers/empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction/)
- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation](https://scholariq.org/papers/antithrombotic-therapy-after-acute-coronary-syndrome-or-pci-in-atrial/)
- [Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome](https://scholariq.org/papers/apixaban-with-antiplatelet-therapy-after-acute-coronary-syndrome/)
- [Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-peripheral-or/)
- [Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure](https://scholariq.org/papers/angiotensin-receptor-neprilysin-inhibition-compared-with-enalapril-on-the-risk/)
- [Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure](https://scholariq.org/papers/cardiac-myosin-activation-with-omecamtiv-mecarbil-in-systolic-heart-failure/)
- [Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure](https://scholariq.org/papers/sacubitril-valsartan-across-the-spectrum-of-ejection-fraction-in-heart-failure/)
- [Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin](https://scholariq.org/papers/safety-of-proton-pump-inhibitors-based-on-a-large-multi-year-randomized-trial-of/)
- [Empagliflozin after Acute Myocardial Infarction](https://scholariq.org/papers/empagliflozin-after-acute-myocardial-infarction/)
- [The Role of Nutraceuticals in Statin Intolerant Patients](https://scholariq.org/papers/the-role-of-nutraceuticals-in-statin-intolerant-patients/)
- [A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial](https://scholariq.org/papers/a-multifaceted-intervention-to-improve-treatment-with-oral-anticoagulants-in/)

## Researcher topics

- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)

## Researcher university

- [Carol Davila University of Medicine and Pharmacy](https://scholariq.org/institutions/carol-davila-university-of-medicine-and-pharmacy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.